T Rowe Price Group CapEx decreased by 7.0% to $62.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 24.4%, from $82.00M to $62.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 3.5% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $63.00M | $56.90M | $60.40M | $54.90M | $67.90M | $54.40M | $60.40M | $60.70M | $71.70M | $93.60M | $81.90M | $102.50M | $103.30M | $104.60M | $113.00M | $82.00M | $62.20M | $63.30M | $66.70M | $62.00M |
| QoQ Change | — | -9.7% | +6.2% | -9.1% | +23.7% | -19.9% | +11.0% | +0.5% | +18.1% | +30.5% | -12.5% | +25.2% | +0.8% | +1.3% | +8.0% | -27.4% | -24.1% | +1.8% | +5.4% | -7.0% |
| YoY Change | — | — | — | — | +7.8% | -4.4% | +0.0% | +10.6% | +5.6% | +72.1% | +35.6% | +68.9% | +44.1% | +11.8% | +38.0% | -20.0% | -39.8% | -39.5% | -41.0% | -24.4% |